Lutathera & pluvicto
Ended Awarded Last action
- Contract number
- 36C25725N0190
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $2,669,629
Award facts
- Contract value 100% obligated
- $2,669,628.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $34,294 | |
| Funding Only Action | -$1,471,057 | |
| Original award | $4,106,392 |
About this award
Novartis Pharmaceuticals Corporation received a delivery order award from Veterans Integrated Service Network 17 (VISN 17) on February 7, 2025, for an increase in quantity of two specialized radiopharmaceutical cancer therapies: LUTATHERA (Lutetium Lu-177 dotatate) and PLUVICTO (Lutetium Lu-177 vipivotide tetra). The contract is structured as a firm fixed-price delivery order with a ceiling value of $2.67 million and an ultimate completion date of February 6, 2026. This award operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) without a small business set-aside designation, allowing Novartis to compete directly in the federal marketplace. The place of performance is listed as East Hanover, New Jersey, which serves as the company's headquarters location.
This delivery order is issued under an existing Indefinite Delivery Contract between Novartis and the Defense Health Agency, established on October 1, 2024, with a $26.1 million ceiling extending through September 30, 2029. The underlying contract authorizes federal healthcare procurement of specialized oncology and nuclear medicine treatments to support the Department of Veterans Affairs' healthcare mission and veteran care programs. Novartis, a large foreign-owned pharmaceutical manufacturer, is a major federal supplier of these advanced cancer therapies and has received extensive federal contract awards across multiple Veterans Integrated Service Networks and the Defense Health Agency for similar radiopharmaceutical products.
Quick answers
Who was awarded contract 36C25725N0190?
36C25725N0190 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 17 (Veterans Health Administration) on February 7, 2025.
How much is contract 36C25725N0190 worth?
The government has obligated $2,669,629 on 36C25725N0190.
Is contract 36C25725N0190 an order under another contract?
Yes. 36C25725N0190 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25725N0190 competed?
The extent of competition for 36C25725N0190 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award